Sevelamer Carbonate Tablet, Film Coated
Product Images NDC 51407-706

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Sevelamer Carbonate (NDC 51407-706). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-706-27ol (Sevelamer Tablets 800 mg)

Label for Sevelamer Carbonate tablets, 800 mg dosage strength. The film-coated tablets are supplied in a package containing 270 tablets. The label includes the NDC 51407-706-27 and is marketed by GSMS, Incorporated in Camarillo, California. Storage and handling instructions as well as a barcode are also present.*

FDA Label Image

Figure2 (Figure 2)

A forest plot chart illustrating subgroup analyses comparing Sevelamer Carbonate versus placebo across various groups including Screening BSA, Baseline Serum Phosphorus levels, Age, and Dialysis status. The chart shows mean differences with 95% confidence intervals, indicating overall and subgroup effects on the measured outcome, with a vertical reference line at zero.*

FDA Label Image

Figure1 (Figure1)

Chemical structure diagram of the active ingredient Sevelamer Carbonate, showing its polymeric amine backbone with ammonium and bicarbonate groups.*

FDA Label Image

Figure3 (Figure3)

A line graph comparing the percentage of patients with at least a 2x reduction in serum phosphorus against the reduction in serum phosphorus levels in mg/dL for Sevelamer Hydrochloride and an Active Control. The graph displays data on changes from baseline, indicating worsening or improvement in serum phosphorus.*

FDA Label Image

Figure4 (Figure4)

A line graph depicting phosphate change from baseline over 52 study weeks. The x-axis shows study weeks from 0 to 52, and the y-axis shows phosphate change values ranging from -5 to 2. Two treatment groups are represented: Sevelamer Hydrochloride (black line with squares) and Active-Control (red line with open squares). The graph illustrates changes in phosphate levels for each group throughout the study period.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.